Erica Schwartz was confirmed as CDC director, filling a nearly yearlong vacancy at the agency. Her confirmation makes her the second permanent leader of the agency since the second Trump administration took office and follows the firing of her predecessor. The article notes current public health challenges the agency faces, including outbreaks of measles and a foodborne parasite in the U.S., and an ongoing Ebola outbreak in parts of Africa. The piece also highlights that observers will watch how Schwartz addresses high-profile policy pressures, including Robert F. Kennedy Jr.’s vaccine policy agenda.
A U.S. committee is scheduled to review measles data and will make a recommendation to the Pan American Health Organization about the country’s measles elimination status. STAT published a First Opinion essay by the committee chair arguing that recent case data signal a reversal of previous public health gains. The article emphasizes that publicly available data are central to the committee’s assessment and that rising measles case counts are cause for concern.
The FDA approved mFlusiva, Moderna’s influenza vaccine formulated using mRNA technology, for older adults. This is the first licensed influenza vaccine made from mRNA. The approval concludes a contentious regulatory episode earlier in the year when the agency’s then-head of biologics issued a rare “refuse-to-file” notice — a decision that had overruled career staff — and that decision was later reversed. The source reports this sequence of events without further technical or efficacy details of the vaccine.
The article summarizes reporting that followed a Science story: a 6-year-old girl died while participating in a Chinese gene-editing clinical trial, and that researchers did not disclose the death at the time. Separately, another Chinese institution belatedly acknowledged the death of a young boy in a Duchenne muscular dystrophy study conducted by HuidaGene. The disclosure prompted questions about transparency and the regulatory environment for investigator‑led or lightly regulated trials in China. A gene‑editing researcher quoted in the source said the lack of transparency is troubling and could mask additional events.
A small clinical trial tested fecal microbiome transplant delivered via stool capsules in children with peanut allergy. Among 15 participants, six showed increased peanut tolerance one month after the transplant, and some maintained increased tolerance as long as four months. The report frames these results as preliminary and notes open questions and next steps for research.
A study published in Nature analyzed longitudinal data from more than 1,100 hospitalized Covid patients and reported that acute SARS‑CoV‑2 infection is associated with reactivation of certain dormant viruses. Two virus families showed significant reactivation during acute Covid: Herpesviridae and Anelloviridae. The study found that reactivation of Anelloviridae, in particular, was strongly associated with long‑term physical disability and long Covid among the hospitalized cohort.
Investigators also observed temporal patterns to reactivation, meaning different viruses tended to reactivate at different times during the course of acute illness. Importantly, the authors reported frequent viral reactivation in people described as “immunocompetent,” which challenges the common presumption that such reactivations primarily affect immunocompromised individuals.
The STAT summary places these findings in the context of earlier research that had linked Covid infection to reactivation of chronic viruses such as Epstein‑Barr virus and cytomegalovirus. The Nature study extends those earlier observations in a larger hospitalized population and ties certain reactivations to clinical outcomes, including disease severity and longer‑term disability.
The STAT article does not provide additional methodological details such as laboratory assays used to detect reactivation, precise timing or frequency data beyond the reported temporal patterns, or specific clinical management implications. It also does not report interventions to prevent or treat viral reactivation in the setting of Covid, nor does it give population‑level incidence estimates outside the hospitalized cohort described.
The Morning Rounds digest concludes with a list of related items readers might find of interest, including pieces from the Wall Street Journal, the New York Times Magazine, STAT coverage of a new narcolepsy drug approval, and an NPR story on a community fight to save a birthing center. These items are linked in the source as additional recommended reading.